Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment: An Alternative Viewpoint

Pharmacotherapy

Volumn 37, Issue 10, 2017, Pages e107-e108

  Roberts, Megan Z ^a   Farley, T Michael ^b   Owens, Ryan E ^c  

^a SAMFORD UNIVERSITY   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c WINGATE UNIVERSITY   (United States)

Author keywords

anticoagulation; arrhythmias; dialysis; drug safety; pharmacokinetics

Indexed keywords

APIXABAN; WARFARIN; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; ATRIAL FIBRILLATION; BODY MASS; DRUG EFFICACY; DRUG LABELING; DRUG SAFETY; HEMODIALYSIS; HUMAN; PEAK-TROUGH FLUCTUATION; SEVERE RENAL IMPAIRMENT; STEADY STATE; TREATMENT DURATION; TREATMENT PLANNING; CHRONIC KIDNEY FAILURE; METABOLISM; PATIENT SAFETY;

ANTICOAGULANTS; HUMANS; KIDNEY FAILURE, CHRONIC; PATIENT SAFETY; PYRAZOLES; PYRIDONES; WARFARIN;

EID: 85028948851     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1993     Document Type: Article

References (6)

1. Stanton BE, Barasch NS, Tellor KB. Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment. Pharmacotherapy 2017;37(4):412–9.
2. Bristol-Meyers Squibb Company. Eliquis (apixaban) package insert. Princeton NJ; 2012. Revised July 2016.
3. Wang X, Tirucherai G, Marbury TC, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol 2016;56:628–36.
4. Deal EN, Pope H, Ross W. Apixaban use among patients with severe renal impairment. Ann Pharmacother 2014;48(12):1667.
5. Mavrakanas TA, Samer CF, Nessim SK, et al. Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol 2017;28:[E-pub ahead of print]. Available from: http://jasn.asnjournals.org/content/early/2017/03/15/ASN.2016090980.long.
6. Avezum A, Lopes RD, Schulte PJ, et al. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Circulation 2015;132(8):624–32.